All lobbying filings

FORBES-TATE

Lobbying for NOVARTIS, INC. · Multinational biopharmaceutical company

Filing Q1 report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 15, 2025

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Bills named in this filing 2

HR 5547
Maintaining Investments in New Innovation Act
S 476
Maintaining Investments in New Innovation Act

Lobbying activity 6

Health Issues

Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.

Medicare/Medicaid

Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act; Issues related to the 340b program.

Trade (domestic/foreign)

Issues related to prescription drug pricing; Issues related to World Trade Organization IP waiver; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.

Budget/Appropriations

Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.

Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.

Taxation/Internal Revenue Code

Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.